| Methods |
RCT comparing ximelagatran versus low molecular weight heparin and warfarin for the treatment of deep vein thrombosis. |
| Data |
2528 patients were randomised (1258/1270, respectively in each treatment group). |
| Comparisons |
Onsite assessment (local investigator blinded) versus assessment by an AC blinded to allocated treatment. |
| Outcomes |
The outcome selected was recurrent venous thromboembolism. The primary composite outcome was recurrent venous thromboembolism, bleeding, and mortality. |
| Notes |
|
| Risk of bias |
| Item |
Authors' judgement |
Description |
| Method for selecting cases to adjudicate? |
No |
All suspect events adjudicated were identified by onsite assessor who was blinded to allocated treatment. |
